These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 17457389

  • 1. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].
    Lehne G, Bjørheim J, Saeter G.
    Tidsskr Nor Laegeforen; 2007 Apr 19; 127(8):1040-4. PubMed ID: 17457389
    [Abstract] [Full Text] [Related]

  • 2. [Current status and problems of tailor-made medicine in anticancer therapy].
    Miya T.
    Gan To Kagaku Ryoho; 2007 Apr 19; 34(4):515-9. PubMed ID: 17431334
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacogenetics of anticancer drugs].
    de Chaisemartin L, Loriot MA.
    Pathol Biol (Paris); 2005 Mar 19; 53(2):116-24. PubMed ID: 15708657
    [Abstract] [Full Text] [Related]

  • 4. Pharmacogenetics for individualized cancer chemotherapy.
    Efferth T, Volm M.
    Pharmacol Ther; 2005 Aug 19; 107(2):155-76. PubMed ID: 15890408
    [Abstract] [Full Text] [Related]

  • 5. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
    Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A.
    Oncologist; 2007 Aug 19; 12(8):913-23. PubMed ID: 17766650
    [Abstract] [Full Text] [Related]

  • 6. [Genomic markers and anticancer chemotherapy].
    Nishiyama M.
    Gan To Kagaku Ryoho; 2008 Feb 19; 35(2):194-9. PubMed ID: 18281756
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y.
    Gan To Kagaku Ryoho; 2003 Mar 19; 30(3):325-33. PubMed ID: 12669388
    [Abstract] [Full Text] [Related]

  • 8. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
    Ansari M, Krajinovic M.
    Curr Opin Pediatr; 2007 Feb 19; 19(1):15-22. PubMed ID: 17224657
    [Abstract] [Full Text] [Related]

  • 9. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
    Lee W, Lockhart AC, Kim RB, Rothenberg ML.
    Oncologist; 2005 Feb 19; 10(2):104-11. PubMed ID: 15709212
    [Abstract] [Full Text] [Related]

  • 10. CYP450 pharmacogenetics for personalizing cancer therapy.
    van Schaik RH.
    Drug Resist Updat; 2008 Jun 19; 11(3):77-98. PubMed ID: 18486526
    [Abstract] [Full Text] [Related]

  • 11. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.
    Clin Cancer Res; 2008 May 01; 14(9):2878-86. PubMed ID: 18451256
    [Abstract] [Full Text] [Related]

  • 12. Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy.
    Mladosievicova B, Carter A, Kristova V.
    Neoplasma; 2007 May 01; 54(3):181-8. PubMed ID: 17447847
    [Abstract] [Full Text] [Related]

  • 13. Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicine.
    Anderson JE, Hansen LL, Mooren FC, Post M, Hug H, Zuse A, Los M.
    Drug Resist Updat; 2006 May 01; 9(4-5):198-210. PubMed ID: 17011811
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of fixed dosing of new anticancer agents in phase I studies.
    Levêque D.
    Anticancer Res; 2008 May 01; 28(5B):3075-7. PubMed ID: 19031959
    [Abstract] [Full Text] [Related]

  • 15. Interpreting disparate responses to cancer therapy: the role of human population genetics.
    Maitland ML, DiRienzo A, Ratain MJ.
    J Clin Oncol; 2006 May 10; 24(14):2151-7. PubMed ID: 16682733
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic drug monitoring of cancer chemotherapy.
    Alnaim L.
    J Oncol Pharm Pract; 2007 Dec 10; 13(4):207-21. PubMed ID: 18045780
    [Abstract] [Full Text] [Related]

  • 17. [Problems associated with molecular targeted drugs for cancer].
    Kawaishi M, Koizum F, Nishio K.
    Gan To Kagaku Ryoho; 2006 Oct 10; 33(10):1373-9. PubMed ID: 17033223
    [Abstract] [Full Text] [Related]

  • 18. [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
    Nishiyama M.
    Gan To Kagaku Ryoho; 2005 Nov 10; 32(12):1902-7. PubMed ID: 16282724
    [Abstract] [Full Text] [Related]

  • 19. Using genetic variation to optimize cancer chemotherapy.
    McLeod HL, Papageorgio C, Watters JW.
    Clin Adv Hematol Oncol; 2003 Feb 10; 1(2):107-11. PubMed ID: 16224389
    [Abstract] [Full Text] [Related]

  • 20. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.
    Zitvogel L, Kepp O, Aymeric L, Ma Y, Locher C, Delahaye NF, André F, Kroemer G.
    Cancer Res; 2010 Dec 01; 70(23):9538-43. PubMed ID: 21098713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.